Anti-Human CD195 (CCR5) – Purified in vivo PLATINUM™ Functional Grade

CHO cells transfected with full-length human CD195 (CCR5).

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone HEK/1/85a/7a recognizes an epitope on human CCR5.

CCR5 is expressed on memory T cells, macrophages, and immature dendritic cells (DCs).

CCR5 antibody, HEK/1/85a/7a, recognizes C-C chemokine receptor type 5 (CCR5), also known as CD195, CC-CKR-5, CHEMR13, and HIV-1 fusion coreceptor. CCR5 is a 45 kDa seven-transmembrane G-protein-coupled receptor (GPCR). CCR5 is expressed on a subset of memory T cells, macrophages, and immature dendritic cells (DCs) and is upregulated by proinflammatory cytokines^1,2. CCR5 binds to inflammatory CC-chemokines, including CCL3 (macrophage inflammatory protein (MIP)-1α), CCL4 (MIP-1β), and RANTES, which increases intracellular calcium levels and results in cytoskeletal rearrangement and chemotactic cell migration³. CCR5 is also the coreceptor for HIV-1 following binding of viral gp120 to CD4^4-7. The levels of CCR5 on cells influence the rate of entry of HIV-1, and patients with lower levels of CCR5 exhibit immunity against infection⁸. CCR5 also contributes to other human diseases, including type I diabetes⁹ and cancer¹⁰.

1. Mackay CR., et al. (1997) Proc Natl Acad Sci. 94(5):1925-30
2. Doms RW., et al. (1999) Proc Natl Acad Sci. 96(9):5215-5220
3. Parmentier M., et al. (1996) Biochemistry. 35(11):3362-7
4. Berger EA., et al. (1996) Science. 272(5270):1955-8
5. Sodroski J., et al. (1996) Cell. 1996 85(7):1135-48
6. Doms RW., et al. (1996) Cell. 85(7):1149-58
7. Paxton WA., et al. (1996) Nature. 381(6584):667-73
8. Sheppard HW., et al. (1997) Nat Med. 3(10):1160-2
9. Delovitch TL., et al. (2000) J Immunol. 165(2):1102-10
10. Casagrande N., et al. (2020) Cancers (Basel). 12(7):1765